Transgenic Analysis of Human Drug–Metabolizing Enzymes: Preclinical Drug Development and Toxicology

Table 5.

Receptor and Transcription Factor Deletions

Gene Phenotype Genetic Background Comments Citation
a 50% perinatal mortality, survivors apparently viable, fertile and normal. b Genetic background enriched to at least 75% C57BL/6 to increase postnatal survival of PPARδ null pups to Mendelian ratios.
AhR Hepatic fibrosis and impaired immune system 129xC57BL/6 Disruption of exon 1 leads to 50% mortality in perinatal period Resistant to TCDD toxicity Reduced retinoic acid metabolism (42)
Viable, fertile but with hepatic defects 129xC57BL/6 Disruption of exon 2 (43)
Viable, fertile 129xC57BL/6 Disruption of exon 2; lacZ reporter Resistant to BaP carcinogenicity (41)
ARNT Embryonic lethal 129xC57BL/6 Disruption of bHLH domain Defects in neural tube closure, embryo rotation (46)
Embryonic lethal Not stated Disruption of bHLH domain Defective angiogenesis of yolk sac and branchial arches, stunted development (45)
Loss of induction via AhR in liver 129xC57BL/6 Disruption of exon 6 Conditional deletion (Mx-1-Cre) (47)
Nrf2 None 129xC57BL/6 Disruption of exons 4,5; lacZ reporter Increased sensitivity to acetaminophen (49)
Develop autoimmune nephritis >60 weeks old 129xICR Disruption of exon 5; lacZ reporter Increased sensitivity to acetaminophen (50)
AhR/Nrf2 Nonea 129xC57BL/6xICR Response to 3MC and BHA abolished (55)
PPARα None 129xC57BL/6 Disruption of exon 8 Lack of response to peroxisome proliferators (57)
PPARδ Reduced growth; Smaller gonadal adipose stores; Reduced brain myelination; Increased epidermal hyperplastic response to TPA 129xC57BL/6b Disruption of last exon (59)
PPARγ Embryonic lethal Not stated Disruption of zinc finger coding region (61)
Altered cholesterol homeostasis 129xC57BL/6 Conditional deletion (macrophages) (62)

This Article

  1. MI September 2003 vol. 3 no. 6 331-343